The Quack AI (Q) token briefly rose 10.73% to 0.036 USDT on September 28, driven by Bithumb's announcement to add a Korean won trading pair for Q. After reaching the short-term high, Q settled at 0.035 USDT. This new listing on Bithumb will provide fresh market activity and trading opportunities for Q, although the exact launch date for the Korean won pairs has not been disclosed yet.
Quack AI's Q token saw a brief 10.73% gain to 0.036 USDT on September 28. For readers following the broader cryptocurrency market, here is Pluang's snapshot as of Sep 28, 2026 11:21 WIB: out of 50 major cryptocurrencies priced on Pluang, 12 rose and 37 fell today. Notable movers include ONE (Harmony) up 23.77% at Rp50 with a typical hold time of 152 days and a Pluang order activity of 30% Sell / 70% Buy, GRT (The Graph) up 19.85% at Rp587 with 87% Sell / 13% Buy order activity, and BAL (Balancer) up 11.14% at Rp16.297 with a typical hold time of 85 days.
Acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), was linked to an 18% lower risk of death, hospitalization, and disease progression compared to tafamidis in a large U.S. electronic health record study of 2,684 patients. The stud...
Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...
Donaldson Company is rated Buy due to its strong recurring replacement demand and diversified filtration portfolio that supports margin recovery and growth. The company's installed base and aftermarket sales provide resilience, while acquisitions lik...
Latigo Biotherapeutics is currently trading below its IPO value despite showing strong potential with its drug onzotrigine, which has demonstrated better efficacy in acute pain compared to Vertex's Journavx. The company benefits from leveraging Verte...
